The ABBA CORD trial, sponsored by Dr. Leland Metheny at the Case Comprehensive Cancer Center, aims to evaluate the efficacy of abatacept in reducing acute graft versus host disease (aGVHD) in patients undergoing double umbilical cord blood transplants (dCBT). Given the high incidence of aGVHD in this patient population, successful outcomes could position abatacept as a critical adjunct therapy, enhancing the standard of care which currently includes tacrolimus and mycophenolate mofetil (MMF). The trial's focus on a diverse patient demographic, particularly those with limited donor options, aligns with ongoing efforts to improve transplant outcomes in underrepresented populations. The potential market for aGVHD prophylaxis is significant, with increasing numbers of cord blood transplants being performed. Competitive analysis indicates that while anti-thymocyte globulin has been previously utilized, its decline in favorability opens a niche for abatacept if proven effective. Diligence should focus on the trial's recruitment progress and regulatory pathways for abatacept as a transplant adjunct.